company background image
SYN

Synthetic Biologics NYSEAM:SYN Stock Report

Last Price

US$1.04

Market Cap

US$16.5m

7D

-19.4%

1Y

-78.8%

Updated

26 Sep, 2022

Data

Company Financials +
SYN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

SYN Stock Overview

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.

Synthetic Biologics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Synthetic Biologics
Historical stock prices
Current Share PriceUS$1.04
52 Week HighUS$4.95
52 Week LowUS$1.03
Beta1.32
1 Month Change-31.58%
3 Month Change-48.00%
1 Year Change-78.78%
3 Year Change-77.08%
5 Year Change-99.68%
Change since IPO-99.82%

Recent News & Updates

Shareholder Returns

SYNUS BiotechsUS Market
7D-19.4%-5.3%-6.9%
1Y-78.8%-30.6%-23.7%

Return vs Industry: SYN underperformed the US Biotechs industry which returned -30% over the past year.

Return vs Market: SYN underperformed the US Market which returned -23% over the past year.

Price Volatility

Is SYN's price volatile compared to industry and market?
SYN volatility
SYN Average Weekly Movement11.5%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: SYN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: SYN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a16Steve Shallcrosshttps://www.syntheticbiologics.com

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.

Synthetic Biologics, Inc. Fundamentals Summary

How do Synthetic Biologics's earnings and revenue compare to its market cap?
SYN fundamental statistics
Market CapUS$16.48m
Earnings (TTM)-US$17.78m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SYN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$17.78m
Earnings-US$17.78m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.12
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.4%

How did SYN perform over the long term?

See historical performance and comparison